Biohaven Pharma (BHVN) Tops Q2 EPS by 6c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. SPY
3. GLOB
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. MU

Go back to Biohaven Pharma (BHVN) Tops Q2 EPS by 6c, Revenues Beat

Biohaven Pharmaceutical Holding (BHVN) PT Raised to $98 at Wedbush, After Financing Agreement Announcement

August 7, 2020 1:36 PM EDT

Wedbush analyst Laura Chico raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $98.00 (from $94.00) while maintaining a Outperform rating.

... More

Biohaven Pharma (BHVN) Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street

August 7, 2020 9:52 AM EDT

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced that it entered into a $500 million non-dilutive term loan financing facility with Sixth Street, a leading global investment firm.

The Sixth Street term loan facility will be available to Biohaven under the following terms:

Up to $500M in a structured term loan facility. Biohaven will use the proceeds for the development, promotion, and commercial launch of NURTEC ODT, as well as for... More

Biohaven Pharma (BHVN), Royalty Pharma (RPRX) Announce Funding Agreement Totaling up to $450 Million

August 7, 2020 9:38 AM EDT

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the company's CGRP receptor antagonist program through the development of zavegepant (formerly known as vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indications. In exchange for these funds, Royalty Pharma will obtain a 0.4% royalty on annual worldwide net sales of Nurtec® ODT and if certain zavegepant regulatory approvals are achieved, a royalty of up to 3% on... More